Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
Austin Health, Melbourne, Victoria, Australia
Medizinische Universitaet Wien, Vienna, Austria
Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria
Institut Daniel Hollard, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France
CHU Caen, Caen, France
AP-HP Henri Mondor, Créteil, France
U.O. Oncologia 2 Universitaria, Pisa, PI, Italy
University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
University of Kansas Cancer Center - North, Kansas City, Missouri, United States
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
NSHA-QEII Health Sciences Centre-Dickson Bldg-Dept. of Medical Oncology ( Site 0200), Halifax, Nova Scotia, Canada
Shizuoka Cancer Center ( Site 1706), Nagaizumi, Shizuoka, Japan
Herlev and Gentofte Hospital-Department of Oncology ( Site 0704), Copenhagen, Hovedstaden, Denmark
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica, Firenze, Italy
Azienda Ospedaliera Niguarda Ca' Granda, Milano, Italy
Instituto Europeo di Oncologia, Milano, Italy
University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece
Rambam Health Care Campus, Haifa, Israel
Hadassah University Medical Centre, Jerusalem, Israel
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.